Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
6.75M
-
Number of holders
-
18
-
Total 13F shares, excl. options
-
2.58M
-
Shares change
-
+2.56M
-
Total reported value, excl. options
-
$57.1M
-
Value change
-
+$56.8M
-
Number of buys
-
14
-
Number of sells
-
-1
-
Price
-
$22.00
Significant Holders of Monopar Therapeutics - Common Stock, $0.001 par value (MNPR) as of Q4 2024
18 filings reported holding MNPR - Monopar Therapeutics - Common Stock, $0.001 par value as of Q4 2024.
Monopar Therapeutics - Common Stock, $0.001 par value (MNPR) has 18 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2.58M shares
of 6.75M outstanding shares and own 38.2% of the company stock.
Largest 10 shareholders include JANUS HENDERSON GROUP PLC (1.05M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (599K shares), RA CAPITAL MANAGEMENT, L.P. (511K shares), Point72 Asset Management, L.P. (168K shares), ADAR1 Capital Management, LLC (130K shares), VANGUARD GROUP INC (56.5K shares), GEODE CAPITAL MANAGEMENT, LLC (38.6K shares), BlackRock, Inc. (8.1K shares), UBS Group AG (6.42K shares), and Ikarian Capital, LLC (5.91K shares).
This table shows the top 18 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.